Brief Summary of Potential SARS-CoV-2 Prophylactic and Treatment Drugs in the Emergency Department.
West J Emerg Med
; 21(3): 510-513, 2020 Mar 31.
Article
em En
| MEDLINE
| ID: mdl-32302280
ABSTRACT
As of March 30th, 2020 there were 161,807 total cases and 2,953 total deaths of SARS-CoV-2 in the United States, with the number of cases expected to rise. Other than supportive care, there are no SARS-CoV-2 specific treatments available for patients discharged from the emergency department (ED) or those admitted to the hospital. In addition, there are no vaccines available to protect our at-risk healthcare workers. The National Institutes of Health is conducting a Phase 1 clinical trial to evaluate for a potential vaccine and the recipients have started to receive the investigational vaccine.2 We present a brief overview of the potential prophylactic and treatment agents under investigation, some which could be initiated in the ED if proven effective.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Pneumonia Viral
/
Infecções por Coronavirus
/
Coronavirus
Limite:
Humans
País/Região como assunto:
America do norte
Idioma:
En
Revista:
West J Emerg Med
Ano de publicação:
2020
Tipo de documento:
Article